Comparison Brainstorm Cell Therapeutics (BCLI) with Competitors
Brainstorm Cell Therapeutics (BCLI) industry is Biotechnology.
Debt-to-Equity
BCLI-12.07%
Industry28.27%
Upside-40.34%
Free Cash Flow Yield
BCLI-62.09%
Industry-1.75%
Upside-60.34%
P/E
BCLI-1.09
Industry-20.52
Upside+1942.56%